Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen

Burgos, Ana Martínez-Cañavate; Torres-Borrego, J.; Terán, Ana Belén Molina; Corzo, José Luís; García, Blanca E.; Pacheco, Ramón Rodríguez; Moreno‐Aguilar, Carmen; Dávila, Ignacio

doi:10.1111/pai.12866

Cited by 23 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a prospective study with 476 patients with polysensitization to inhaled and food allergens, 175 the molecular diagnostic approach changed the prescription of AIT in about 50% of patients, which also decreased the cost of AIT. Martinez-Canavate Burgos et al observed in 281 children with double sensitization to olive and grass, 300 and Del-Rio Camacho et al 301 observed in 70 children with various sensitizations, that the AIT prescription was changed in more than 50% after PAMD@; Del-Rio Camacho et al also noted that the proportion of AIT prescriptions for a single allergen increased from 18% to 51%. Similarly, the use of PAMD@ changed prescriptions in 42%-48% of 651 children in an Italian study.…”

Section: Molecular Diagnosis and Allergen Immunotherapymentioning

confidence: 98%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

View full text Add to dashboard Cite

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

show abstract

Section: Molecular Diagnosis and Allergen Immunotherapymentioning

confidence: 98%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

“…The ability of defining the genuine sensitization profile (thus to rule out the confounding role of pan‐allergens as cause of false positivity at standard tests) also allowed to obtain a more and more detailed prescription profile. It was clearly documented that the molecular‐based diagnosis could lead to a significant change, estimated in about 40%‐50% in the SLIT prescription as compared to the standard diagnostic approaches . Notably, it was shown that as larger is the sensitization profile, as greater is the AIT failure .…”

Section: Present Future and Unmet Needs Of Slitmentioning

confidence: 99%

30 years of sublingual immunotherapy

Passalacqua

Bagnasco

Canonica

2019

Allergy

View full text Add to dashboard Cite

Allergen Immunotherapy (AIT) was introduced in clinical practice on an empirical basis more than 100 years ago. Since the first attempts, AIT was administered subcutaneously. Indeed, other routes of administration were proposed and studied, in particular to improve the safety, but only the sublingual route (SLIT) achieved a credibility based on evidence and was then accepted as a viable “alternative” option to the subcutaneous route. SLIT was largely used in clinical trials and clinical practice in this last 30 years. Thus, a large amount of data is available, coming from either controlled trials and postmarketing surveillance studies. It is clear that SLIT is overall effective, but it is also clear that the efficacy is not “class‐related,” as derived from meta‐analyses, but restricted to each specific product. The 30‐year lasting use of SLIT allowed to clarify many clinical aspects, such as efficacy, safety, use in asthma, regimens of administration, and optimal doses. In parallel, the mechanisms of action of AIT were elucidated, and new indications were proposed (eg food allergy, atopic dermatitis). In addition, the introduction of molecular‐based diagnosis, allowed to better refine the prescription of SLIT, based on specific sensitization profiles. The present article will describe the origin and evolution of SLIT for respiratory allergy, taking into account the clinical context that suggested this form of treatment, the recently developed aspects, the future perspectives and unmet needs, This is not, therefore, a systematic review, rather a narrative historical description of the past history, and a look forward to the future opportunities.

show abstract

“…Grass and olive pollen seasons in Spain overlap and so it is difficult to identify the true nature of the allergen in patients with seasonal AR. The molecular sensitization pattern revealed that most patients (76.2%) in a Spanish paediatric population were sensitized to both major grass (PhI p 1 + 5) and olive (Ole e 1) pollen allergens …”

Section: Allergen Immunotherapy (Ait)mentioning

confidence: 99%

“…The molecular sensitization pattern revealed that most patients (76.2%) in a Spanish paediatric population were sensitized to both major grass (PhI p 1 + 5) and olive (Ole e 1) pollen allergens. 120 Very preterm-born children are predisposed to respiratory diseases due to improper lung maturation. Protein supplementation of preterm formula and maternal milk improves lung function at 6 years of age.…”

Section: Allerg En Immunother Apy ( Ait )mentioning

confidence: 99%

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

Allergy

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

show abstract

Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen

Abstract: Double sensitization to grass and olive pollen is common in Spain and also occurs in the pediatric population. Molecular diagnosis using specific IgE may help improve immunotherapy selection in polysensitized patients.

Cited by 23 publications

References 25 publications

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

30 years of sublingual immunotherapy

Highlights and recent developments in airway diseases in EAACI journals (2018)

Contact Info

Product

Resources

About